Drugs / DT01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01469455 | Oct 2011 → Jul 2015 | metastatic melanoma | DNA Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05719896 | Feb 2023 → Dec 2024 | irritable bowel syndrome | Centre of Clinical Pharmacology, Hanoi Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01469455 ↗ |
| Action | Inhibit | “DNA Repair Inhibitor” NCT01469455 ↗ |
| Route | Subcutaneous | “peritumoral subcutaneous” NCT01469455 ↗ |